中图分类号R95；R817 文献标志码A 文章编号 1001-0408(2025)15-1825-07

    DOI 10.6039/j.issn.1001-0408.2025.15.01

    Expert consensus on the phase O clinical trials of positron-emiting radiopharmaceuticals (2O25 edition) WANG Lu¹ ，WANG Jinghao2，HU Kuan3，YAO Dongning4，CAI Benzhi5，SHI Chen6，YANG Baofeng'，WANG Rui3 (1.Dept.of Nuclear Medicine，the First Afiliated Hospital of Jinan University，Guangzhou 510630，China; 2.Dept.of Pharmacy，the First Afiliated Hospital of Jinan University，Guangzhou 510630，China;3.Institute of Materia Medica，Chinese Academy of Medical Sciences，Beijing 10oo50，China;4. School of Pharmacy， Nanjing Medical University，Nanjing 21166，China;5. Dept.of Pharmacy，the Second Afiliated Hospital of Harbin Medical University，Harbin 150086，China;6.Dept.of Pharmacy，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan 430022，China;7. School of Pharmacy， Harbin Medical University，Harbin150081，China)

    ABSTRACTOBJECTIVETo provideareference forstandardizingtheconductof postron-emitingradiopharmaceuticals’phase Oclinicaltrials(hereinafterreferredtoas“phaseOclinicaltrials”)andadvancingthedevelopmentof innovativedrugbymedical institutios.METHODSInitiatedbytheFirstAfiliatedHospitalofJinanUniversity ......